Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core–shell protein nanoparticle

Scalable production of microscopic particles for biological delivery

“…In an effort to extend it to industrial production method, Wacker et al utilized a paddle stirring system to replace the magnetic stirring used in lab-scale preparation. 82 A production scale of 2 gram protein was achieved, with the nanoparticle size ranging between 251.2 AE 27.0 and 234.1 AE 1.5 nm and with the polydispersity index 83 Further homogenization treatment was conducted to coat a mucoadhesive layer of sodium alginate for enhanced oral delivery of sorafenib. 83 Clinically, the most notable albumin nanoparticle is the socalled nab-paclitaxel (trade name Abraxane s ), which is based on high-pressure homogenization of the anticancer drug paclitaxel with albumin, forming nanoparticles with a diameter of roughly 130 nm.…”

“…82 A production scale of 2 gram protein was achieved, with the nanoparticle size ranging between 251.2 AE 27.0 and 234.1 AE 1.5 nm and with the polydispersity index 83 Further homogenization treatment was conducted to coat a mucoadhesive layer of sodium alginate for enhanced oral delivery of sorafenib. 83 Clinically, the most notable albumin nanoparticle is the socalled nab-paclitaxel (trade name Abraxane s ), which is based on high-pressure homogenization of the anticancer drug paclitaxel with albumin, forming nanoparticles with a diameter of roughly 130 nm. [84][85][86] Hybrid microscopic particles containing both polymers and lipids have also been explored for biological delivery.…”

“…In another effort of scalable production, Gopakumar et al employed high-pressure homogenization, yielding gram-scale of albumin nanoparticles encapsulating sorafenib (a small-molecule multi-kinase inhibitor). 83 Further homogenization treatment was conducted to coat a mucoadhesive layer of sodium alginate for enhanced oral delivery of sorafenib. 83 Clinically, the most notable albumin nanoparticle is the socalled nab-paclitaxel (trade name Abraxane s ), which is based on high-pressure homogenization of the anticancer drug paclitaxel with albumin, forming nanoparticles with a diameter of roughly 130 nm.…”

High Drug Loading Nanoparticles Stabilized with Autologous Serum Proteins Passively Inhibits Tumor Growth

“…These endogenous biomacromolecules, like proteins, DNA, polysaccharide, and lipoproteins, perform a wide range of roles toward intracellular communication, molecular transport, structural reinforcement, and catalysis . Natural proteins, especially albumin, known for its intrinsic drug transport property, have been on the forefront due to adaptable drug binding domains, their ability to extend drug circulation time, high accumulation in tumors, biodegradability, and negligible immunogenicity. , Scalable techniques such as high pressure homogenization have been well demonstrated for encapsulation of drug molecules with serum protein based nanoparticles. , Other biomacromolecules, such as lipids, apolipoproteins, collagen, and glycogen, have been reported as nanocarriers of therapeutic molecules and nanoconstructs for tissue-engineering applications. , …”

“…2,3 Scalable techniques such as high pressure homogenization have been well demonstrated for encapsulation of drug molecules with serum protein based nanoparticles. 4,5 Other biomacromolecules, such as lipids, apolipoproteins, collagen, and glycogen, have been reported as nanocarriers of therapeutic molecules and nanoconstructs for tissue-engineering applications. 6,7 Despite their successful demonstration, there are persisting challenges with nanodrug delivery systems, and low drug loading (<10 wt %) is a prominent issue that stands out.…”